EPO and neoplasm: While systemically administered Epo co-activates adverse effects such as overproduction of blood cells increasing the risk of thrombosis and promotion of tumor growth, some Epo-mimetics including EV-3 selectively stimulate tissue protection without activating homodimeric EpoR-associated side effects.